Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK 1,908.00
0.00 (0.00%)
Jul 28, 2026, 4:59 PM CET
Genmab Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,901 | 3,720 | 3,121 | 2,390 | 2,084 | 1,287 | |
Revenue Growth | 20.66% | 19.19% | 30.59% | 14.68% | 61.88% | -22.52% |
Cost of Revenue | 261 | 238 | 143 | 33 | - | - |
Gross Profit | 3,640 | 3,482 | 2,978 | 2,357 | 2,084 | 1,287 |
Selling, General & Admin | 666 | 626 | 549 | 478 | 384.48 | 196.24 |
Research & Development | 1,687 | 1,606 | 1,414 | 1,107 | 799.14 | 639.51 |
Operating Expenses | 2,353 | 2,232 | 1,963 | 1,585 | 1,184 | 835.75 |
Operating Income | 1,287 | 1,250 | 1,015 | 772 | 900.43 | 451.68 |
Interest Expense | -168 | -61 | -18 | -10 | -5.6 | -1.99 |
Interest & Investment Income | 119 | 138 | 144 | 142 | 46.55 | 30.13 |
Currency Exchange Gain (Loss) | -22 | -3 | 92 | -66 | 151.01 | 224.85 |
EBT Excluding Unusual Items | 1,216 | 1,324 | 1,233 | 838 | 1,092 | 704.67 |
Merger & Restructuring Charges | -230 | -185 | -43 | - | - | - |
Gain (Loss) on Sale of Investments | 48 | 65 | 136 | -21 | -94.54 | -105.39 |
Pretax Income | 1,034 | 1,204 | 1,326 | 817 | 997.85 | 599.28 |
Income Tax Expense | 213 | 241 | 193 | 186 | 214.51 | 146.99 |
Net Income | 821 | 963 | 1,133 | 631 | 783.33 | 452.29 |
Net Income to Common | 821 | 963 | 1,133 | 631 | 783.33 | 452.29 |
Net Income Growth | -27.73% | -15.00% | 79.56% | -19.45% | 73.19% | -42.16% |
Shares Outstanding (Basic) | 62 | 62 | 64 | 65 | 65 | 65 |
Shares Outstanding (Diluted) | 63 | 63 | 65 | 66 | 66 | 66 |
Shares Change | -2.55% | -3.04% | -1.88% | -0.17% | -0.06% | 0.24% |
EPS (Basic) | 13.24 | 15.49 | 17.65 | 9.66 | 11.98 | 6.92 |
EPS (Diluted) | 13.11 | 15.37 | 17.53 | 9.58 | 11.87 | 6.85 |
EPS Growth | -25.81% | -12.32% | 82.98% | -19.27% | 73.29% | -42.30% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 872 | 1,149 | 1,099 | 1,018 | 516.52 | 302.24 |
Free Cash Flow Per Share | 13.91 | 18.33 | 17.00 | 15.45 | 7.83 | 4.58 |
Gross Margin | 93.31% | 93.60% | 95.42% | 98.62% | 100.00% | 100.00% |
Operating Margin | 32.99% | 33.60% | 32.52% | 32.30% | 43.21% | 35.08% |
Profit Margin | 21.05% | 25.89% | 36.30% | 26.40% | 37.59% | 35.13% |
Free Cash Flow Margin | 22.35% | 30.89% | 35.21% | 42.59% | 24.79% | 23.48% |
EBITDA | 1,330 | 1,290 | 1,052 | 802 | 941.81 | 481.35 |
EBITDA Margin | 34.09% | 34.68% | 33.71% | 33.56% | 45.19% | 37.39% |
D&A For EBITDA | 43 | 40 | 37 | 30 | 41.38 | 29.67 |
EBIT | 1,287 | 1,250 | 1,015 | 772 | 900.43 | 451.68 |
EBIT Margin | 32.99% | 33.60% | 32.52% | 32.30% | 43.21% | 35.08% |
Effective Tax Rate | 20.60% | 20.02% | 14.56% | 22.77% | 21.50% | 24.53% |